ALPEGA-GROUP
9.6.2022 14:02:10 CEST | Business Wire | Press release
Alpega Group, a leading European SaaS software company for the transportation industry, announced today that it has reached an agreement to acquire Road Heroes, Truck Driver Platform from Pinetco. Road Heroes is a specialized job site that links truck drivers with prospective employers.
With the current global supply chain strain, shortages of drivers is increasingly creating the bottleneck that will not go away once production ramps to otherwise open supply chains back up. While Alpega provides shippers the opportunity to contract carriers long term, to spot bid through its TMS solutions and manages some of the largest freight exchanges in Europe, the problem of driver shortage is still a blocking point in the chain.
It is estimated that Europe has a shortage of 400,000 truck drivers today. The reasons for this are well documented ranging from a generational retirement of older drivers, lack of work/life balance sought by younger drivers, difficulties of work environment due to road congestion and even lack of parking for trucks in major cities. Many younger people who might be interested in driving have just said ‘no thanks’.
Road Heroes by Alpega provides a European-wide platform for hiring companies and prospective drivers to showcase ‘why us’ and ‘why me’, in an effort to give both parties a competitive edge to fulfil the market needs. The platform comes with a lot of intelligence under the hood, which allows a specific matching between job offers and truck drivers to maximize the relevance.
Efficiency of supply chains, specifically the transportation leg of the supply chain, is increasingly becoming a focus as demand for goods grows, congestion on the motorways skyrockets and inflation hits every pocketbook in the world. Add to this, the environmental impact of empty trucks on the road and the unnecessary carbon emissions those trucks produce.
Being able to have the right trucks at the right place at the right time with full loads, loaded and unloaded as efficiently as possible and then allowing those trucks to take the next load to the next location without downtime or ‘empty backhauls’ helps ease the supply chain strain.
”At Alpega we view our responsibility to the transportation industry as a holistic one involving people, processes and the software tools to move goods as efficiently as possible. Connecting our driver community with our carrier, freight forwarder and shipper communities is a role we are willing and able to play and a natural fit for us. Road Heroes is a next step in our effort to build the largest digital logistics platform in Europe” said Fabrice Douteaud, General Manager, Alpega Freight Exchanges.
The Road Heroes transaction is expected to close in June with availability of Road Heroes by Alpega targeted for July.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
